Literature DB >> 17415628

Fighting against sudden death: a single or multidisciplinary approach.

John G F Cleland1, Periaswamy Velavan, Mansour Nasir.   

Abstract

There are many causes of sudden death ranging from accidents and suicide to vascular events and arrhythmias. Most sudden deaths will occur in people who have not been diagnosed with a serious heart condition but at a very low annual rate. Many of these events are probably vascular and might be prevented by reducing the risk of developing coronary disease. Only a minority of sudden deaths occur in people with established cardiac disease, but in patients with major structural heart disease, the annual rate is high. The causes of sudden death are many in this clinical setting also, but dominated by ventricular arrhythmias and vascular events. There is good evidence that conventional treatments for heart failure, including ACE inhibitors, beta-blockers, aldosterone antagonists and cardiac resynchronization devices reduce the risk of sudden death. Evidence that statins, aspirin or revascularisation are safe or effective in patients with heart failure is currently lacking. Implantable defibrillators confer a small but definite additional survival advantage by treating arrhythmias that have not been prevented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415628     DOI: 10.1007/s10840-006-9077-6

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.759


  40 in total

Review 1.  Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease.

Authors:  John G F Cleland
Journal:  Prog Cardiovasc Dis       Date:  2002 Jan-Feb       Impact factor: 8.194

Review 2.  Is aspirin safe for patients with heart failure?

Authors:  J G Cleland; C J Bulpitt; R H Falk; I N Findlay; C M Oakley; G Murray; P A Poole-Wilson; C R Prentice; G C Sutton
Journal:  Br Heart J       Date:  1995-09

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  beta Blockade after myocardial infarction: systematic review and meta regression analysis.

Authors:  N Freemantle; J Cleland; P Young; J Mason; J Harrison
Journal:  BMJ       Date:  1999-06-26

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction.

Authors:  Stein Orn; John G F Cleland; Matti Romo; John Kjekshus; Kenneth Dickstein
Journal:  Am J Med       Date:  2005-07       Impact factor: 4.965

7.  Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.

Authors:  Philip Jong; Salim Yusuf; Michel F Rousseau; Sylvie A Ahn; Shrikant I Bangdiwala
Journal:  Lancet       Date:  2003-05-31       Impact factor: 79.321

8.  Timing of sudden death in patients with heart failure.

Authors:  D K Moser; W G Stevenson; M A Woo; L W Stevenson
Journal:  J Am Coll Cardiol       Date:  1994-10       Impact factor: 24.094

9.  Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction.

Authors:  A Farb; A L Tang; A P Burke; L Sessums; Y Liang; R Virmani
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

10.  The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.

Authors:  J G F Cleland; I Findlay; S Jafri; G Sutton; R Falk; C Bulpitt; C Prentice; I Ford; Adele Trainer; P A Poole-Wilson
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.